coherusbiosciences

Coherus Oncology is a public, fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (PD-1) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal, and other cancers.